Ginkgo Bioworks Reports Third Quarter 2025 Financial Results
Ginkgo Bioworks (NYSE: DNA) reported third quarter 2025 results on November 6, 2025: Total revenue $39M (down 56% year‑over‑year, prior year included $45M non‑cash deferred revenue), Cell Engineering $29M, Biosecurity $9M. GAAP net loss was $81M and Adjusted EBITDA was $(56)M. Cash, cash equivalents and marketable securities were $462M as of September 30, 2025.
Company reaffirmed full‑year 2025 guidance: Total revenue $167–$187M, Cell Engineering $117–$137M, Biosecurity at least $40M. Business highlights include a multi‑year extension with Bayer and a BARDA project award up to $22.2M. A webcast and replay are available for investors.
L'azienda ha confermato le previsioni per l'intero 2025: Entrate totali $167–$187M, Cell Engineering $117–$137M, Biosecurity almeno $40M. I principali elementi operativi includono una estensione pluriennale con Bayer e un premio di progetto BARDA fino a $22.2M. È disponibile un webcast e la relativa replica per gli investitori.
La empresa reafirmó las expectativas para todo 2025: Ingresos totales $167–$187M, Cell Engineering $117–$137M, Biosecurity al menos $40M. Entre los aspectos destacados se incluyen una extensión multianual con Bayer y un premio de proyecto BARDA de hasta $22.2M. Un webcast y su repetición están disponibles para los inversores.
회사는 2025년 연간 가이던스를 재확인했다: 총매출 $167–$187M, Cell Engineering $117–$137M, Biosecurity 최소 $40M. 주요 사업 하이라이트로는 바이어와의 다년 계약 연장 및 BARDA 프로젝트 수주 최대 $22.2M이 포함된다. 투자자를 위한 웹캐스트와 재방송이 제공된다.
La société a confirmé ses prévisions pour l'ensemble de l'année 2025 : Chiffre d'affaires total 167–187 M$, Cell Engineering 117–137 M$, Biosecurity au moins 40 M$. Parmi les points forts figurent une extension pluriannuelle avec Bayer et une attribution de projet BARDA jusqu'à $22.2M. Un webcast et sa rediffusion sont disponibles pour les investisseurs.
Das Unternehmen bestätigte die Guidance für das Geschäftsjahr 2025: Gesamtumsatz $167–$187M, Cell Engineering $117–$137M, Biosecurity mindestens $40M. Zu den Geschäftshighlights gehören eine mehrjährige Verlängerung mit Bayer und eine BARDA-Projektzuwendung von bis zu $22.2M. Ein Webcast und eine Replay stehen für Investoren zur Verfügung.
وأكدت الشركة توجيهات السنة المالية 2025 بالكامل: الإيرادات الإجمالية 167–$187M، Cell Engineering 117–$137M، Biosecurity على الأقل $40M. تشمل النقاط البارزة توسيعًا متعدد السنوات مع Bayer وجائزة مشروع BARDA حتى $22.2M. يوجد بث ويب ومتابعة للمستثمرين.
- Cash, cash equivalents and marketable securities of $462M as of Sept 30, 2025
- Reaffirmed full‑year 2025 total revenue guidance of $167–$187M
- BARDA project award with total contract value up to $22.2M
- Extended multi‑year strategic partnership with Bayer for agricultural R&D
- Q3 2025 total revenue $39M, down 56% year‑over‑year
- Q3 2025 Cell Engineering revenue $29M, down 61% year‑over‑year
- GAAP net loss of $81M in Q3 2025
- Adjusted EBITDA of $(56)M in Q3 2025 (worse than prior year)
Insights
Ginkgo reports a sharply smaller Q3 revenue base and wider loss, but reaffirms full‑year guidance and retains a sizable liquidity buffer.
Third quarter results show Total revenue of
Dependencies and risks are explicit in the release: near‑term comparisons are distorted by the prior‑year accounting item, and current operating losses persist per the GAAP and adjusted metrics. Concrete revenue drivers disclosed include continued work with Bayer, a BARDA project award with a contract value up to
Ginkgo provides an update on its third quarter financial results
Third Quarter 2025 Financial Results
- Third quarter 2025 Total revenue of
$39 million $89 million 56% , which prior year included$45 million 11% from the comparable prior year period.- Third quarter 2025 Cell Engineering revenue of
$29 million $75 million 61% , which prior year included the above noted$45 million - Third quarter 2025 Biosecurity revenue of
$9 million $14 million
- Third quarter 2025 Cell Engineering revenue of
- Third quarter 2025 GAAP net loss of
$(81) million $(56) million - Third quarter 2025 Adjusted EBITDA of
$(56) million $(20) million - Cash, cash equivalents and marketable securities balance as of September 30, 2025 of
$462 million
"Our recent partnership announcements are powerful examples of how Ginkgo's AI-enabled cloud lab technology can be deployed to accelerate
Recent Business Highlights & Strategic Positioning
- We believe AI models will impact biotechnology in two ways and Ginkgo is well-positioned to provide tools in both
- First, we see reasoning models controlling lab automation. Since science moves forward on the back of lab data and reasoning models are already capable of planning and analyzing experiments, we believe coupling reasoning models to automation will allow science to move as fast as human ideas.
- Second, we see AI models that predict and generate new biological discoveries. Protein models such as AlphaFold prove the potential of large AI models. These models require the type of large training sets of biological data that Ginkgo provides.
- We continue to offer research solutions on top of our in-house robotics, winning us new deals in Agriculture and with the
U.S. Government- We announced the extension of our multi-year strategic partnership with Bayer to continue advancing the research and development of biological products for agriculture. The collaboration, which began in 2017, will build on the success of developing an innovative nitrogen fixation platform, and Bayer continues to be a major partner for Ginkgo's expanded agricultural biologicals R&D platform.
- We were recently awarded a project agreement through the Biomedical Advanced Research and Development Authority's (BARDA) BioMaP-Consortium with a total contract value of up to
$22.2 million
- We are expanding our frontier autonomous lab in
Boston as a showcase. Please visit!- We'll soon have 46 major instruments on 36 Reconfigurable Automation Carts (RACs). With these RACS, we can apply AI reasoning models and "lab in the loop" to your scientific challenges. Upon successful proof-of-concept, we can build and install a system so you can run it at your own site.
- We can have your workflows running on the system in a matter of weeks if we have the required equipment. Reach out for a demo!
Full Year 2025 Outlook
- Ginkgo reaffirms Total revenue of
$167 -$187 million - Ginkgo continues to expect Cell Engineering revenue of
$117 -$137 million - Ginkgo continues to expect Biosecurity revenue of at least
$40 million
- Ginkgo continues to expect Cell Engineering revenue of
Conference Call Details
Ginkgo will host a video conference today, Thursday, November 6, 2025, beginning at 4:30 p.m. ET. The presentation will include an overview of the third quarter of 2025, recent business updates, a discussion on Ginkgo's outlook, as well as a moderated question and answer session.
To ask a question ahead of the presentation, please submit your questions to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to investors@ginkgobioworks.com.
A webcast link is available on Ginkgo's Investor Relations website and a replay will be made available following the presentation.
Ginkgo Investor Website: https://investors.ginkgobioworks.com/events/
Audio-Only Dial Ins:
+1 646 876 9923 (
+1 301 715 8592 (
+1 305 224 1968 (
+1 312 626 6799 (
+1 346 248 7799 (
+1 408 638 0968 (
+1 564 217 2000 (
+1 689 278 1000 (
Webinar ID: 953 3421 4604
If you experience technical difficulties with any of these dial-ins or if you need international dial-in numbers, please visit our website at https://investors.ginkgobioworks.com/events/ for updated dial-in information.
About Ginkgo Bioworks
Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. Ginkgo R&D Solutions delivers customizable R&D packages—such as protein engineering, nucleic acid design, and cell-free systems—giving partners a comprehensive way to accelerate innovation across therapeutics, diagnostics, & manufacturing. Ginkgo Automation sells modular, integrated laboratory automation so scientists can spend their days planning and analyzing experiments rather than pipetting in the lab. Ginkgo Datapoints uses Ginkgo's in-house automation to generate the large lab data sets to power your AI models. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.
Forward-Looking Statements of Ginkgo Bioworks
This press release, the presentation, and the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, including with respect to technology adaptations to meet our customers' needs, strategies, including with respect to our current expectations, operations and anticipated results of operations, both business and financial, including the timing for attaining Adjusted EBITDA breakeven, impacts of our restructuring, potential customer success, including successful application of our offerings by our customers, expected benefits from our strategic partnerships, and expectations with regard to revenue, including our ability to meet all milestones and achieve the maximum revenue available under certain of our customer arrangements, expenses, our full year 2025 outlook, and the market environment, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs and Codebase assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith and (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies, including potential adverse effects from the
Use of Non-GAAP Financial Measures
Certain of the financial measures included in this release, including Adjusted EBITDA and non-GAAP revenue, have not been prepared in accordance with generally accepted accounting principles ("GAAP"), and constitute "non-GAAP financial measures" as defined by the SEC. Ginkgo has included these non-GAAP financial measures because it believes they provide an additional tool for investors to use in evaluating Ginkgo's financial performance and prospects. Due to the nature and/or size of the items being excluded, such items do not reflect future gains, losses, expenses or benefits and are not indicative of our future operating performance. These non-GAAP financial measures are supplemental to, and should not be considered in isolation from, or as an alternative to, financial measures determined in accordance with GAAP. In addition, these non-GAAP financial measures may differ from non-GAAP financial measures with comparable names used by other companies. See the reconciliation below for additional information regarding certain of the non-GAAP financial measures included in this release, including a description of these non-GAAP financial measures and a reconciliation of the historic measures to Ginkgo's most comparable GAAP financial measures.
Ginkgo Bioworks Contacts:
INVESTOR CONTACT:
investors@ginkgobioworks.com
MEDIA CONTACT:
press@ginkgobioworks.com
|
Ginkgo Bioworks Holdings, Inc. |
|||
|
|
|||
|
|
As of September |
|
As of December |
|
Assets |
|
|
|
|
Current assets: |
|
|
|
|
Cash and cash equivalents |
$ 111,065 |
|
$ 561,572 |
|
Marketable securities |
350,797 |
|
— |
|
Accounts receivable, net |
21,430 |
|
21,857 |
|
Accounts receivable - related parties |
929 |
|
586 |
|
Prepaid expenses and other current assets |
21,861 |
|
18,729 |
|
Total current assets |
506,082 |
|
602,744 |
|
Property, plant and equipment, net |
176,579 |
|
203,720 |
|
Operating lease right-of-use assets |
368,213 |
|
394,435 |
|
Investments |
30,175 |
|
48,704 |
|
Intangible assets, net |
61,522 |
|
72,510 |
|
Other non-current assets |
46,594 |
|
55,336 |
|
Total assets |
$ 1,189,165 |
|
$ 1,377,449 |
|
Liabilities and Stockholders' Equity |
|
|
|
|
Current liabilities: |
|
|
|
|
Accounts payable |
$ 10,704 |
|
$ 14,169 |
|
Deferred revenue (includes |
25,236 |
|
27,710 |
|
Accrued expenses and other current liabilities |
79,341 |
|
65,387 |
|
Total current liabilities |
115,281 |
|
107,266 |
|
Non-current liabilities: |
|
|
|
|
Deferred revenue, net of current portion (includes |
74,072 |
|
98,783 |
|
Operating lease liabilities, non-current |
422,870 |
|
438,766 |
|
Other non-current liabilities |
17,159 |
|
16,576 |
|
Total liabilities |
629,382 |
|
661,391 |
|
Commitments and contingencies (Note 10) |
|
|
|
|
Stockholders' equity: |
|
|
|
|
Preferred stock, |
— |
|
— |
|
Common stock, |
6 |
|
5 |
|
Additional paid-in capital |
6,627,350 |
|
6,555,416 |
|
Accumulated deficit |
(6,069,569) |
|
(5,837,557) |
|
Accumulated other comprehensive income (loss) |
1,996 |
|
(1,806) |
|
Total stockholders' equity |
559,783 |
|
716,058 |
|
Total liabilities and stockholders' equity |
$ 1,189,165 |
|
$ 1,377,449 |
|
Ginkgo Bioworks Holdings, Inc. |
|||||||
|
|
|||||||
|
|
Three Months Ended |
|
Nine Months Ended |
||||
|
|
2025 |
|
2024 |
|
2025 |
|
2024 |
|
Cell Engineering revenue (1) |
$ 29,380 |
|
$ 75,089 |
|
$ 106,744 |
|
$ 139,183 |
|
Biosecurity revenue |
9,457 |
|
13,957 |
|
30,015 |
|
44,013 |
|
Total revenue |
38,837 |
|
89,046 |
|
136,759 |
|
183,196 |
|
Costs and operating expenses: |
|
|
|
|
|
|
|
|
Cost of Biosecurity revenue |
8,177 |
|
9,987 |
|
25,576 |
|
30,996 |
|
Cost of other revenue |
4,625 |
|
2,016 |
|
14,095 |
|
3,930 |
|
Research and development |
69,353 |
|
77,006 |
|
193,646 |
|
347,684 |
|
General and administrative |
44,954 |
|
52,292 |
|
137,276 |
|
188,864 |
|
Goodwill impairment |
— |
|
— |
|
— |
|
47,858 |
|
Restructuring charges |
1,745 |
|
2,949 |
|
10,692 |
|
20,015 |
|
Total operating expenses |
128,854 |
|
144,250 |
|
381,285 |
|
639,347 |
|
Loss from operations |
(90,017) |
|
(55,204) |
|
(244,526) |
|
(456,151) |
|
Other income (expense): |
|
|
|
|
|
|
|
|
Interest income, net |
5,742 |
|
9,251 |
|
17,906 |
|
31,275 |
|
Gain (loss) on investments |
3,684 |
|
(6,912) |
|
(238) |
|
(16,282) |
|
Loss on deconsolidation of subsidiary |
— |
|
(7,013) |
|
— |
|
(7,013) |
|
Change in fair value of warrant liabilities |
— |
|
1,528 |
|
— |
|
5,701 |
|
Other income (expense), net |
(163) |
|
1,572 |
|
(5,348) |
|
2,821 |
|
Total other income (expense) |
9,263 |
|
(1,574) |
|
12,320 |
|
16,502 |
|
Loss before income taxes |
(80,754) |
|
(56,778) |
|
(232,206) |
|
(439,649) |
|
Income tax (benefit) expense |
1 |
|
(375) |
|
(194) |
|
(154) |
|
Net loss |
$ (80,755) |
|
$ (56,403) |
|
$ (232,012) |
|
$ (439,495) |
|
Net loss per share: |
|
|
|
|
|
|
|
|
Basic |
$ (1.45) |
|
$ (1.08) |
|
$ (4.22) |
|
$ (8.58) |
|
Diluted |
$ (1.45) |
|
$ (1.08) |
|
$ (4.22) |
|
$ (8.58) |
|
Weighted average common shares outstanding: |
|
|
|
|
|
|
|
|
Basic |
55,633,718 |
|
52,240,559 |
|
54,916,539 |
|
51,244,332 |
|
Diluted |
55,633,718 |
|
52,246,129 |
|
54,916,539 |
|
51,249,902 |
|
Comprehensive loss: |
|
|
|
|
|
|
|
|
Net loss |
$ (80,755) |
|
$ (56,403) |
|
$ (232,012) |
|
$ (439,495) |
|
Other comprehensive (loss) income: |
|
|
|
|
|
|
|
|
Foreign currency translation adjustment |
27 |
|
494 |
|
3,462 |
|
(2,713) |
|
Reclassification of foreign currency translation |
— |
|
1,492 |
|
— |
|
1,492 |
|
Unrealized gains (loss) on available-for-sale |
316 |
|
— |
|
340 |
|
— |
|
Total other comprehensive (loss) income |
343 |
|
1,986 |
|
3,802 |
|
(1,221) |
|
Comprehensive loss |
$ (80,412) |
|
$ (54,417) |
|
$ (228,210) |
|
$ (440,716) |
|
|
|
|
(1) |
Includes related party revenue of zero and |
|
Ginkgo Bioworks Holdings, Inc. |
|||
|
|
|||
|
|
Nine Months Ended September |
||
|
|
2025 |
|
2024 |
|
Cash flows from operating activities: |
|
|
|
|
Net loss |
$ (232,012) |
|
$ (439,495) |
|
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
Depreciation and amortization |
45,327 |
|
47,368 |
|
Stock-based compensation |
60,519 |
|
91,783 |
|
Goodwill impairment |
— |
|
47,858 |
|
Restructuring related impairment charges |
— |
|
4,823 |
|
Loss on investments |
275 |
|
16,282 |
|
Loss on deconsolidation of subsidiary |
— |
|
7,013 |
|
Change in fair value of notes receivable |
5,685 |
|
— |
|
Change in fair value of warrant liabilities |
— |
|
(5,701) |
|
Change in fair value of contingent consideration |
(4,232) |
|
3,698 |
|
Non-cash lease expense |
22,449 |
|
20,619 |
|
Non-cash in-process research and development |
— |
|
19,796 |
|
Accretion of discount on marketable securities |
(2,502) |
|
|
|
Other non-cash activity |
1,611 |
|
655 |
|
Changes in operating assets and liabilities: |
|
|
|
|
Accounts receivable |
345 |
|
(6,101) |
|
Prepaid expenses and other current assets |
(70) |
|
3,487 |
|
Operating lease right-of-use assets |
3,814 |
|
19,224 |
|
Other non-current assets |
(38) |
|
(196) |
|
Accounts payable, accrued expenses and other current liabilities |
16,991 |
|
(31,099) |
|
Deferred revenue, current and non-current (7,958) and (50,858) from related parties |
(27,209) |
|
(67,779) |
|
Operating lease liabilities, current and non-current |
(18,793) |
|
(11,383) |
|
Other non-current liabilities |
4,459 |
|
1,998 |
|
Net cash used in operating activities |
(123,381) |
|
(277,150) |
|
Cash flows from investing activities: |
|
|
|
|
Purchases of marketable debt securities |
(401,838) |
|
— |
|
Maturities of marketable debt securities |
73,599 |
|
— |
|
Purchases of property and equipment |
(7,660) |
|
(48,831) |
|
Business acquisition |
— |
|
(5,400) |
|
Proceeds from sales of marketable securities |
— |
|
3,951 |
|
Proceeds from sale of equipment |
— |
|
591 |
|
Other |
511 |
|
538 |
|
Net cash used in investing activities |
(335,388) |
|
(49,151) |
|
Cash flows from financing activities: |
|
|
|
|
Proceeds from ATM offering |
10,317 |
|
— |
|
Payment of issuance costs related to ATM offering |
(355) |
|
— |
|
Proceeds from exercise of stock options |
— |
|
84 |
|
Principal payments on finance leases |
(329) |
|
(694) |
|
Contingent consideration payment |
— |
|
(922) |
|
Other |
— |
|
(4) |
|
Net cash provided by (used in) financing activities |
9,633 |
|
(1,536) |
|
Effect of foreign exchange rates on cash and cash equivalents |
353 |
|
(208) |
|
Net decrease in cash, cash equivalents and restricted cash |
(448,783) |
|
(328,045) |
|
|
|
|
|
|
Cash and cash equivalents, beginning of period |
561,572 |
|
944,073 |
|
Restricted cash, beginning of period |
44,171 |
|
45,511 |
|
Cash, cash equivalents and restricted cash, beginning of period |
605,743 |
|
989,584 |
|
|
|
|
|
|
Cash and cash equivalents, end of period |
111,065 |
|
616,214 |
|
Restricted cash, end of period |
45,895 |
|
45,325 |
|
Cash, cash equivalents and restricted cash, end of period |
$ 156,960 |
|
$ 661,539 |
|
Ginkgo Bioworks Holdings, Inc. |
||||||
|
|
||||||
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
|||
|
|
2025 |
2024 |
|
2025 |
|
2024 |
|
Cell Engineering |
|
|
|
|
|
|
|
Revenue |
$ 29,380 |
$ 75,089 |
|
$ 106,744 |
|
$ 139,183 |
|
Costs and operating expenses: |
|
|
|
|
|
|
|
Cost of other revenue |
2,994 |
2,016 |
|
9,980 |
|
3,930 |
|
Research and development |
50,954 |
55,137 |
|
130,689 |
|
221,148 |
|
General and administrative |
12,170 |
23,088 |
|
44,338 |
|
94,534 |
|
Cell Engineering operating loss |
(36,738) |
(5,152) |
|
(78,263) |
|
(180,429) |
|
Biosecurity |
|
|
|
|
|
|
|
Revenue |
9,457 |
13,957 |
|
30,015 |
|
44,013 |
|
Costs and operating expenses: |
|
|
|
|
|
|
|
Cost of Biosecurity revenue |
7,643 |
9,987 |
|
23,449 |
|
30,996 |
|
Research and development |
— |
141 |
|
— |
|
720 |
|
General and administrative |
6,692 |
10,040 |
|
21,443 |
|
33,169 |
|
Biosecurity operating loss |
(4,878) |
(6,211) |
|
(14,877) |
|
(20,872) |
|
Total segment operating loss |
(41,616) |
(11,363) |
|
(93,140) |
|
(201,301) |
|
Reconciling items to reconcile total segment operating |
|
|
|
|
|
|
|
Stock-based compensation (1) |
18,103 |
14,013 |
|
61,429 |
|
94,636 |
|
Goodwill impairment |
— |
— |
|
— |
|
47,858 |
|
Depreciation and amortization |
14,168 |
17,171 |
|
45,327 |
|
47,368 |
|
Restructuring charges (2) |
1,745 |
2,948 |
|
10,692 |
|
20,015 |
|
Carrying cost of excess space (net of sublease income) (3) |
14,328 |
9,274 |
|
38,416 |
|
16,657 |
|
Merger and acquisition related expense (income) (4) |
57 |
(796) |
|
(4,478) |
|
6,110 |
|
Acquired in-process research and development |
— |
— |
|
— |
|
19,849 |
|
Other (income) expense, net (5) |
(9,263) |
2,805 |
|
(12,320) |
|
(14,145) |
|
Loss before income taxes |
$ (80,754) |
$ (56,778) |
|
$ (232,206) |
|
$ (439,649) |
|
|
|
|
(1) |
Includes |
|
|
|
|
(2) |
See Note 3, Restructuring, for composition of costs. |
|
|
|
|
(3) |
The carrying cost of excess space includes base rent, common area maintenance charges, and real estate taxes associated with facilities the Company is not occupying, net of any sublease income from these spaces. |
|
|
|
|
(4) |
Represents transaction and integration costs directly related to mergers and acquisitions, including: (i) legal, consulting, and accounting fees associated with acquisitions; (ii) post-acquisition employee retention bonuses; (iii) (gain)/loss from changes in the fair value of contingent consideration liabilities resulting from acquisitions; and (iv) costs associated with the Zymergen Bankruptcy, as well as securities litigation costs. |
|
|
|
|
(5) |
Includes interest income, interest expense, loss on investments, changes in fair value of certain assets and liabilities, and other gains and losses. |
|
Ginkgo Bioworks Holdings, Inc. |
|||||||
|
|
|||||||
|
|
Three Months Ended |
|
Nine Months Ended |
||||
|
(in thousands) |
2025 |
|
2024 |
|
2025 |
|
2024 |
|
Net loss (1) |
$ (80,755) |
|
$ (56,403) |
|
$ (232,012) |
|
$ (439,495) |
|
Interest income, net |
(5,742) |
|
(9,251) |
|
(17,906) |
|
(31,275) |
|
Income tax (benefit) expense |
1 |
|
(375) |
|
(194) |
|
(154) |
|
Depreciation and amortization |
14,168 |
|
17,171 |
|
45,327 |
|
47,368 |
|
EBITDA |
(72,328) |
|
(48,858) |
|
(204,785) |
|
(423,556) |
|
Stock-based compensation (2) |
18,103 |
|
14,013 |
|
61,429 |
|
94,636 |
|
Goodwill impairment |
— |
|
— |
|
— |
|
47,858 |
|
Restructuring charges (3) |
1,745 |
|
2,949 |
|
10,692 |
|
20,015 |
|
Merger and acquisition related expense (income) (4) |
57 |
|
(796) |
|
(4,478) |
|
6,110 |
|
Loss (gain) on investments |
(3,684) |
|
6,912 |
|
238 |
|
16,282 |
|
Loss on deconsolidation of subsidiary |
— |
|
7,013 |
|
— |
|
7,013 |
|
Change in fair value of warrant liabilities |
— |
|
(1,528) |
|
— |
|
(5,701) |
|
Change in fair value of convertible notes |
400 |
|
281 |
|
5,685 |
|
1,127 |
|
Adjusted EBITDA |
$ (55,707) |
|
$ (20,014) |
|
$ (131,219) |
|
$ (236,216) |
|
|
|
|
(1) |
All periods include non-cash revenue when earned, including |
|
|
|
|
(2) |
Includes |
|
|
|
|
(3) |
Restructuring charges primarily consist of employee termination costs from the reduction in force commenced in June 2024. |
|
|
|
|
(4) |
Represents transaction and integration costs directly related to mergers and acquisitions, including: (i) legal, consulting, and accounting fees associated with acquisitions; (ii) post-acquisition employee retention bonuses; (iii) (gain)/loss from changes in the fair value of contingent consideration liabilities resulting from acquisitions; and (iv) costs associated with the Zymergen Bankruptcy, as well as securities litigation costs. Not included in this adjustment are acquired in-process research and development expenses, which totaled zero for both the three months ended September 30, 2025 and 2024, respectively, and zero and |
View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-reports-third-quarter-2025-financial-results-302607675.html
SOURCE Ginkgo Bioworks
FAQ
What were Ginkgo Bioworks (DNA) Q3 2025 revenue and net loss figures?
How did Ginkgo's Q3 2025 revenue compare year‑over‑year for DNA?
What is Ginkgo's cash position as of September 30, 2025 for DNA?
What full‑year 2025 guidance did Ginkgo (DNA) reaffirm?
What material contracts or partnerships did Ginkgo announce in Nov 2025?
Where can investors access Ginkgo (DNA) Q3 2025 presentation and replay?
